Evaluation of the Carba NP test for carbapenemase detection in Enterobacteriaceae, *Pseudomonas* spp. and *Acinetobacter* spp., and its practical use in the routine work of a national reference laboratory for susceptibility testing

E. Literacka¹ · M. Herda¹ · A. Baraniak² · D. Żabicka¹ · W. Hryniewicz¹ · A. Skoczynska¹ · M. Gniadkowski²

Received: 30 March 2017 / Accepted: 4 July 2017 / Published online: 25 July 2017
© The Author(s) 2017. This article is an open access publication

Abstract The aim of this study was to evaluate the Carba NP test (and CarbAcineto) for the detection of carbapenemases in Enterobacteriaceae, *Pseudomonas* spp. and *Acinetobacter* spp., and to assess its usefulness in the routine work of the National Reference Centre for Susceptibility Testing (NRCST) in Poland. The evaluation of the Carba NP/CarbAcineto tests was carried out on a group of 81 Enterobacteriaceae, *Pseudomonas* spp. and *Acinetobacter* spp. isolates producing KPC-, NDM-, VIM-, IMP- or OXA-48, -23, -24/40, -58-type carbapenemases, and on 26 carbapenemase-negative strains cultivated on a broad panel of microbiological media. Subsequently, the performance of the Carba NP/CarbAcineto tests was assessed on 1282 isolates of Enterobacteriaceae, *Pseudomonas* spp. and *Acinetobacter* spp. from Polish hospitals, submitted to the NRCST during a 9-month period in 2014. The Carba NP/CarbAcineto results were compared with other phenotypic tests and/or polymerase chain reaction (PCR). The impact of the media on the results of the Carba NP/CarbAcineto tests was observed, with the Columbia blood agar yielding the highest sensitivity and clarity of the results. Furthermore, the Carba NP/CarbAcineto tests were included in the NRCST routine procedure for carbapenemase identification. The sensitivity and specificity of the Carba NP test were 95.8% and 93.3%, respectively, for *Enterobacteriaceae*, and 97.5% and 99.0%, respectively, for *Pseudomonas* spp. The sensitivity of the CarbAcineto test for *Acinetobacter* spp. was 88.9%. This study confirmed the usefulness of the Carba NP/CarbAcineto tests for the rapid detection of various types of carbapenemases.

Introduction

The dynamic spread of carbapenemase-producing Enterobacteriaceae, *Pseudomonas* spp. and *Acinetobacter* spp. has been observed all over the world in recent years. The predominant carbapenemases include β-lactamases of the Ambler class A (KPCs), metallo-β-lactamases (MBLs) of the class B (VIMs, IMPs, NDMs) and carbapenem-hydrolysing oxacillinases of the class D (OXA-23, OXA-24/40, OXA-48 or OXA-58 types) [1–9]. Carbapenemase producers notoriously exhibit multidrug resistance phenotypes, making treatment of infections extremely difficult [10–13]. Therefore, quick, unambiguous, easy and cheap identification of carbapenemase-producing bacteria has been one of the priorities of modern clinical microbiology. The biochemical Carba NP test for Enterobacteriaceae and *Pseudomonas* spp., and its variant CarbAcineto for *Acinetobacter* spp., were proposed to address this challenge in 2012 and 2014, respectively [1, 14, 15]. Both tests were reported to have high specificity and sensitivity for all of the major carbapenemase types [1, 14, 15]; however, it was shown that, for some enzymes, the sensitivity relies strongly on the type of microbial medium used for bacteria cultivation [16–18]. The original Carba NP test was soon followed by modified variants, and has been commercialised [19–26].

The aim of this study was to evaluate the Carba NP and CarbAcineto tests for the detection of carbapenemase-producing Enterobacteriaceae, *Pseudomonas* spp. and...
Acinetobacter spp. cultivated on different media. Moreover, the Carba NP/CarbAcineto tests were assessed in the routine diagnostics of carbapenemase producers conducted by the National Reference Centre for Susceptibility Testing (NRCST) in Poland in 2014.

Materials and methods

Assessment of the Carba NP and CarbAcineto tests: strain collection and cultivation media

For the initial evaluation of the Carba NP and CarbAcineto tests, a total of 107 strains were used: 81 carbapenemase producers that were well characterised with phenotypic methods, polymerase chain reaction (PCR) and sequencing, and 26 carbapenemase non-producers, including 21 meropenem-non-susceptible strains (Table 1). Both tests were performed by the in-house protocol as previously described [14, 18]. The results presented are those that were recorded after 2 h of incubation time. For cultivation of bacteria, a number of non-selective or screening media and the Mueller–Hinton ready-to-use agar plates, products of six manufacturers, were used (Tables 2 and 3).

The Carba NP and CarbAcineto tests in routine reference diagnostics

In the second part of this work, the Carba NP and CarbAcineto tests were implemented into the routine activity of the NRCST, which is responsible for the reference diagnostics and surveillance of carbapenemase-producing Gram-negative pathogens in Poland. Both tests were performed along with the phenylboronic acid disc test [27], double-disc synergy test with EDTA (DDST-EDTA) [28], temocillin disc test [29] for the phenotypic detection of KPCs, MBLs and OXA-48 types, respectively [30], spectrophotometric assay for imipenem hydrolysis [31] and PCR for \( \text{bla}_{\text{KPC}}, \text{bla}_{\text{VIM}}, \text{bla}_{\text{IMP}}, \text{bla}_{\text{NDM}}, \text{bla}_{\text{OXA}-48}, \text{bla}_{\text{OXA}-23}, \text{bla}_{\text{OXA}-24/40} \) and \( \text{bla}_{\text{OXA}-58} \)-like genes [32]. This analysis was done on 1282 isolates in total (Table 4), including 915 Enterobacteriaceae, 309 Pseudomonas spp. and 58 Acinetobacter spp. collected from April to the end of December 2014 in hospitals all over Poland. All these isolates were cultivated only on Columbia blood agar plates.

Results

Assessment of the Carba NP and CarbAcineto tests and the cultivation media

For Enterobacteriaceae, the Carba NP test performed well, with the carbapenemase-producing strains cultured on most of the non-selective or screening media (Table 2). False-negative results were obtained only for single isolates with VIMs or OXA-48s grown on three types of chromogenic media. When bacteria were cultivated on Mueller–Hinton (MH) agars, the Carba NP test was positive for all KPC, IMP and all but one OXA-48 producers, while false-negative or questionable results were obtained for NDM- and VIM-producing strains. For a number of carbapenemase-negative strains picked up from some media, the results were questionable and for single strains were false-positive.

The results of the Carba NP test for Pseudomonas spp. strains are presented in Table 3. In the case of carbapenemase (VIM or IMP) producers, the best results were observed for

| Table 1 | Isolates used in the Carba NP/CarbAcineto tests evaluation |
|---------|-----------------------------------------------------------|
| Species, total number | Carbapenemase genes | No. |
| Carbapenemase-positive, \( n = 81 \) |
| Enterobacteriaceae, \( n = 34 \) |
| \( K. \ pneumoniae, n = 15 \) | KPC | 4 |
| | NDM | 5 |
| | VIM | 2 |
| | IMP | 1 |
| | OXA-48 | 3 |
| \( K. \ oxytoca, n = 3 \) | NDM | 1 |
| | VIM | 2 |
| \( E. \ coli, n = 9 \) | KPC | 2 |
| | NDM | 4 |
| | OXA-48 | 3 |
| \( E. \ cloacae, n = 5 \) | KPC | 1 |
| | NDM | 1 |
| | VIM | 3 |
| \( C. \ freundii, n = 2 \) | KPC | 2 |
| Pseudomonas spp., \( n = 15 \) |
| \( P. \ aeruginosa, n = 9 \) | VIM | 8 |
| | IMP | 1 |
| \( P. \ putida, n = 6 \) | VIM | 6 |
| Acinetobacter spp., \( n = 32 \) |
| \( A. \ baumannii \) | VIM | 6 |
| \( A. \ baumannii \) | VIM | 7 |
| \( A. \ baumannii \) | VIM | 3 |
| \( A. \ baumannii \) | OXA-23 | 9 |
| \( A. \ baumannii \) | OXA-24/40 | 6 |
| \( A. \ baumannii \) | OXA-58 | 1 |
| Carbapenemase-negative, \( n = 26^a \) |
| \( K. \ pneumoniae \) | No | 10 |
| \( P. \ aeruginosa \) | No | 6 |
| Acinetobacter spp. | No | 10 |

\(^a\)Of the 26 carbapenemase-negative isolates, 21 isolates were carbapenem-non-susceptible (8 \( K. \ pneumoniae \), 6 \( P. \ aeruginosa \) and 7 \( Acinetobacter \) spp.).
The strains cultivated on the Columbia blood agar, chromID CPS, Brilliance UTI agar (Oxoid) and Brilliance CRE agar (Oxoid). The false-negative results were observed for some isolates cultivated on five other chromogenic media, and on MH (Oxoid) and MHE (bioMérieux) agars. For single carbapenemase-negative strains cultivated on five media, false-positive results were observed.

The results of the CarbAcineto test for \textit{Acinetobacter} spp. strains are shown in Table 3. As in the case of Enterobacteriaceae and \textit{Pseudomonas} spp., the impact of the cultivation medium on CarbAcineto was revealed; moreover, for isolates with OXA-like carbapenemases, the correct results were observed more often than for VIM-positive strains (Table 3).

### Table 2 The results of the Carba NP test for Enterobacteriaceae isolates (34 carbapenemase producers and 10 carbapenemase non-producers) cultivated on a set of microbialia media

| Microbiological media          | Manufacturer | VIM; n = 7\textsuperscript{a} | IMP; n = 1\textsuperscript{a} | NDM; n = 11\textsuperscript{a} | KPC; n = 9\textsuperscript{a} | OXA-48; n = 6\textsuperscript{a} | c-np\textsuperscript{b}; n = 10\textsuperscript{a} |
|--------------------------------|--------------|-------------------------------|-----------------------------|-----------------------------|--------------------------------|-------------------------------|----------------------------------|
|                                |              | + /− − NG (NI) + | + /− − NG (NI) + | + /− − NG (NI) + | + /− − NG (NI) + | + /− − NG (NI) + | + /− − NG (NI) + |
| Columbia blood agar            | BD           | 7                              | 1                            | 10 (1)                      | 9                              | 6                            | 10                              |
| chromID CPS agar               | bioMérieux   | 7                              | 1                            | 11                          | 9                              | 6                            | 10                              |
| CHROMagar Orientation Medium   | BD           | 7                              | 1                            | 11                          | 9                              | 6                            | 1 9                             |
| Brilliance UTI agar            | Oxoid        | 7                              | 1                            | 11                          | 9                              | 5                            | 1                               |
| Brilliance UTI Clarity agar    | Oxoid        | 7                              | 1                            | 11                          | 9                              | 5                            | 1                               |
| Brilliance ESBL agar           | Oxoid        | 6                              | 1                            | 11                          | 9                              | 5                            | 1                               |
| chromID ESBL agar              | bioMérieux   | 7                              | 1                            | 11                          | 9                              | 5                            | 1                               |
| Brilliance CRE agar            | Oxoid        | 6                              | 1                            | 11                          | 8                              | 1                            | 2                               |
| chromID CARBA agar             | bioMérieux   | 3 2                           | 1                            | 10 1                        | 9                              | 5                            | 1                               |
| KPC CHROM agar                 | GRASO        | 7                              | 1                            | 11                          | 9                              | 5                            | 1                               |
| chromID OXA-48 agar            | bioMérieux   | 7                              | 1                            | 11                          | 10                             | 9                            | 6                               |
| MH                             | BD           | 7                              | 1                            | 10 1                        | 9                              | 6                            | 2                               |
| MHE                            | bioMérieux   | 7                              | 1                            | 10 1                        | 9                              | 6                            | 8                               |
| MHE                            | bioMérieux   | 1 6                           | 1                            | 2 3 6                       | 9                              | 6                            | 10                              |
| MH                             | Oxoid        | 7                              | 1                            | 11                          | 9                              | 5                            | 1                               |
| GRASO                          | 7                              | 1                            | 11                          | 9                              | 6                            | 1                               |
| MH                             | Liofilchem   | 7                              | 1                            | 10 1                        | 9                              | 6                            | 9                               |
| MH                             | Bio-Rad      | 5 2                           | 1                            | 2 3 6                       | 9                              | 6                            | 1 1                             |

\textsuperscript{a} +, positive; /−, questionable; −, negative; (NI), not interpretable; NG, no growth

\textsuperscript{b} c-np, carbapenemase-non-producers

The Carba NP and CarbAcineto tests in routine reference diagnostics

The results of the comparison of the Carba NP/CarbAcineto tests with the standard methodology used by the NRCST, obtained with 1282 bacterial isolates suspected of carbapenemase production, are presented in Table 4. The phenotypic tests and PCRs detected various carbapenemases in 451/915 Enterobacteriaceae, 118/309 \textit{Pseudomonas} spp. and 54/58 \textit{Acinetobacter} spp. isolates. For Enterobacteriaceae, the overall sensitivity and positive predictive value (PPV) of Carba NP were 95.8% [95% confidence interval (CI), 93.9–97.6%], and the specificity and negative predictive value (NPV) were 93.3% (95% CI, 90.9–95.6%). For \textit{Pseudomonas} spp. the sensitivity and PPV were 97.5% (95% CI, 94.6–100%), and the specificity and NPV were 99.0% (95% CI, 97.6–100%). For \textit{Acinetobacter} spp., the sensitivity and PPV of CarbAcineto were 88.9% (95% CI, 80.4–97.4%).

Discussion

The Carba NP test was described for the first time in 2012 by Nordmann et al. as a rapid, easy and cheap method for carbapenemase detection in Enterobacteriaceae and \textit{Pseudomonas} spp., with high sensitivity and specificity [1, 15]. In previous studies, the test was evaluated by several groups, often confirming the original observations [2, 19, 33–35]. However, one study undermined the sensitivity in
the case of MBL-producing strains [2]. The problem turned out to be associated with the cultivation medium used [16–18], and the follow-up study by Dortet et al. documented well the impact of microbiological media on the performance of Carba NP [18].

In the first part of this work, well-characterised Enterobacteriacea, Pseudomonas spp. and Acinetobacter spp. strains with various carbapenemases were used, along with a broad panel of commercially available media. The results clearly illustrated the influence of the media on the Carba NP/CarbAcineto tests. According to our experience, the Columbia blood agar is the best choice for the cultivation of bacteria for the Carba NP/CarbAcineto tests, providing the highest sensitivity and clarity of the results. The VIM or NDM producers harvested from most of the MH agars yielded a remarkable number of false-negative results, which were most probably related to lower zinc ions’ concentrations that is crucial for the MBL activity [18]. Owing to the low incidence of OXA-48 producers in Poland so far, only six such isolates were used in this work, and all of these were clearly positive in Carba NP, in contrast to some other reports [17, 25, 34–37]. This study has definitely confirmed the usefulness of the CarbAcineto test for the detection of the acquired carbapenemases in Acinetobacter spp. [8, 38, 39] and for distinguishing such isolates from hyperproducers of the natural OXA-51 types and from the carbapenem-negative carbapenem-non-susceptible isolates, which is important for epidemiological reasons.

The Carba NP and CarbAcineto tests have been used in the NRCST from the end of 2013 and March 2014, respectively, and now are included in its routine algorithm for carbapenemase detection as reliable, inexpensive and easy.

| Microbiological media                  | Carba NP          | CarbAcineto         |
|----------------------------------------|-------------------|---------------------|
|                                        | Pseudomonas spp.  | Acinetobacter spp.  |
|                                        | VIM; n = 14\(^a\) | VIM; n = 16\(^a\)   |
|                                        | IMP; n = 1\(^a\)  | OXA-like; n = 16\(^a\) |
|                                        | c-np\(^b\); n = 6\(^a\) | c-np\(^b\); n = 10\(^a\) |
|                                        | +/−/− NG (NI)     | +/−/− NG (NI)       |
|                                        | +/−/− NG (NI)     | +/−/− NG (NI)       |

| Manufacturer | VIM; n = 14\(^a\) | IMP; n = 1\(^a\) | c-np\(^b\); n = 6\(^a\) |
|--------------|-------------------|------------------|-------------------------|
| Columbia blood agar | 14 1 6           | 16 16 10        |
| chromID CPS agar     | bioMérieux 14 1 6 | 14 2 16 9 (1)  |
| CHROMagar Orientation Medium | BD 13 1 2 4 | 11 4 1 15 1 9 |
| Brilliance UTTI agar     | Oxoid 14 1 3 3 | 12 4 15 1 9 (1) |
| Brilliance UTTI Clarity agar | Oxoid 12 1 2 3 | 14 2 15 1 8 (1) |
| Brilliance ESBL agar   | Oxoid 8 3 2 (1) 1 | 13 2 1 2 6 (1)  |
| chromID ESBL agar     | bioMérieux 12 1 1 1 1 4 1 | 14 1 1 15 1 8 (1) |
| Brilliance CRE agar    | Oxoid 14 1 3 1 | 10 2 4 15 1 7 2 (1) |
| chromID CARBA agar     | bioMérieux 10 1 3 1 | 10 6 15 1 8 2 |
| KPC CHROM agar        | GRASO 12 2 1 6 | 11 2 3 15 1 8 2 |
| chromID OXA-48 agar   | bioMérieux 3 3 8 1 | 3 3 1 9 6 9 2 4 1 3 7 |
| MH                      | Bio-Rad 9 5 1 1 5 | 16 16 1 1 8 |
| MH                      | Liofilchem 13 1 1 | 16 14 1 1 10 |
| MH                      | GRASO 13 1 1 6 | 16 16 1 8 (1) |
| MH                      | BD 14 1 6 | 16 15 1 1 2 7 |
| MH                      | Oxoid 13 1 1 | 16 16 10 |
| MHE                     | bioMérieux 14 1 | 16 16 9 (1) |
| MHF                     | bioMérieux 5 3 6 1 | 11 3 2 15 1 8 (1) |

\(^{a}\) +, positive; \(^{b}\)/−, questionable; −, negative; (NI), not interpretable; NG, no growth

\(^{b}\) c-np, carbapenemase-non-producers
Table 4  Performance of the Carba NP/CarbAcineto tests in the analysis of 1282 surveillance isolates submitted to the National Reference Centre for Susceptibility Testing (NRCST) from April to December 2014

| Enterobacteriaceae (total, n = 915) | Pseudomonas spp. (total, n = 309) | Acinetobacter spp. (total, n = 58) |
|-----------------------------------|-----------------------------------|----------------------------------|
| Carbapenemase-positive, n = 451   | Carbapenemase-positive, n = 118   | Carbapenemase-positive, n = 54   |
| Carba NP positive, n = 432        | Carba NP positive, n = 115        | CarbAcineto positive, n = 48     |
| KPC, n = 77                       | VIM, n = 115                      | A. baumannii VIM, n = 2           |
| K. pneumoniae, n = 75             | P. aeruginosa, n = 111            | A. lwoffii VIM, n = 3             |
| E. coli, n = 1                    | P. putida, n = 4                  | A. junii VIM, n = 3               |
| E. cloacae, n = 1                 |                                    | A. baumannii OXA-24/40-like, n = 30|
| NDM, n = 275                     |                                    | A. baumannii OXA-23-like, n = 10  |
| K. pneumoniae, n = 267            |                                    |                                  |
| E. coli, n = 2                    |                                    |                                  |
| E. cloacae, n = 4                 |                                    |                                  |
| S. marcescens, n = 2              |                                    |                                  |
| VIM, n = 57                       |                                    |                                  |
| K. pneumoniae, n = 12             |                                    |                                  |
| E. coli, n = 6                    |                                    |                                  |
| E. cloacae, n = 26                |                                    |                                  |
| C. freundii, n = 8                |                                    |                                  |
| S. marcescens, n = 4              |                                    |                                  |
| K. oxytoca, n = 1                 |                                    |                                  |
| OXA-48, n = 23                    |                                    |                                  |
| K. pneumoniae, n = 7              |                                    |                                  |
| E. coli, n = 14                   |                                    |                                  |
| E. aerogenes, n = 2               |                                    |                                  |
| Carba NP questionable, n = 18     | Carba NP questionable, n = 3       | CarbAcineto questionable, n = 6  |
| K. pneumoniae NDM, n = 14         | P. aeruginosa VIM, n = 3           | A. baumannii OXA-24/40-like, n = 1|
| K. pneumoniae OXA-48, n = 1       |                                    | A. baumannii OXA-23-like, n = 3  |
| E. coli OXA-48, n = 1             |                                    | A. baumannii OXA-58, n = 2       |
| E. cloacae KPC, n = 1             |                                    |                                  |
| C. freundii VIM, n = 1            |                                    |                                  |
| Carba NP not interpretable, n = 1 | K. pneumoniae NDM, n = 1           |                                  |
| Carbenapenemase-negative, n = 464 |                                    |                                  |
| Carba NP negative, n = 433        |                                    |                                  |
| Carba NP questionable, n = 30     | Carba NP questionable, n = 2       | CarbAcineto negative, n = 4      |
| K. pneumoniae, n = 19             | P. aeruginosa, n = 2               |                                  |
| E. cloacae, n = 9                 |                                    |                                  |
| S. marcescens, n = 1              |                                    |                                  |
| P. mirabilis, n = 1               |                                    |                                  |

Carba NP not interpretable, n = 1

| K. pneumoniae, n = 1 |
|---------------------|
| Sensitivity 95.8%    |
| (95% CI, 93.9–97.6%) |
| Specificity 93.3%    |
| (95% CI, 90.9–95.6%) |
| PPV 95.8%           |
| (95% CI, 93.9–97.6%) |
| NPV 93.3%           |
| (95% CI, 90.9–95.6%) |

a PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval
screening tests, reducing remarkably the time for the first feedback information for clinical laboratories. Based on own experience, and in the context of the alarming spread of carbapenemase-producing Gram-negative pathogens in Poland, the NRCST has been recommending Carba NP/CarbAcineteto tests for use in diagnostic microbiology laboratories all over the country.

Acknowledgements We thank Paweł Urbanowicz for his technical support, and the microbiologists from all the centres sending the isolates to the National Reference Centre for Susceptibility Testing (NRCST) in Poland.

Compliance with ethical standards

Funding This study was partially financed by the health programme “Narodowy Program Ochrony Antybiotyków na lata 2011–2015” from the Polish Ministry of Health, by the grant SPUB MIKROBANK from the Polish Ministry of Science and Higher Education and by the statutory funding from the Ministry of Science and Higher Education, Poland.

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval The authors declare that ethical approval was not required. The study was conducted using the isolates sent to the NRCST for reference diagnostics.

Informed consent The authors declare that informed consent was not required.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References
1. Nordmann P, Poirel L, Dortet L (2012) Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 18:1503–1507. doi: 10.3201/eid1809.120355
2. Tijet N, Boyd D, Patel SN, Mulvey MR, Melano RG (2013) Evaluation of the Carba NP test for rapid detection of carbapenemase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:4578–4580. doi: 10.1128/AAC.00788-13
3. Dortet L, Poirel L, Nordmann P (2014) Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int 2014:249856. doi: 10.1155/2014/249856. Review
4. Albigé B, Glaser C, Struelens MJ, Grundmann H, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group (2015) Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 20(45)
5. Baraniak A, Izedbski R, Fiett J, Gawryszewska I, Bojarska K, Herda M, Literacka E, Žabicka D, Tomczak H, Pewinska N, Szarata M, Ozorowski T, Milner A, Hryniewicz W, Gniadkowski M (2016) NDM-producing Enterobacteriaceae in Poland, 2012–14: inter-regional outbreak of Klebsiella pneumoniae ST11 and sporadic cases. J Antimicrob Chemother 71:85–91. doi: 10.1093/jac/dkv282
6. Baraniak A, Izedbski R, Fiett J, Herda M, Derde LP, Bonten MJ, Adler A, Carmeli Y, Goossens H, Hryniewicz W, Brun-Buisson C, Gniadkowski M; MOSAR WP2, WP3, and WP5 Study Groups (2015) KPC-like carbapenemase-producing Enterobacteriaceae colonizing patients in Europe and Israel. Antimicrob Agents Chemother 60:1912–1917. doi: 10.1128/AAC.02756-15
7. Nordmann P, Poirel L (2014) The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 20(9):821–830. doi: 10.1111/1469-0691.12719. Review
8. Poirel L, Naas T, Nordmann P (2010) Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob Agents Chemother 54:24–38. doi: 10.1128/AAC.01512-08. Review
9. Pitout JD, Nordmann P, Poirel L (2015) Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59:5873–5884. doi: 10.1128/AAC.01019-15. Review
10. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. doi: 10.1111/j.1469-0691.2011.03570.x
11. Schwaber MJ, Carmeli Y (2008) Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 300:2911–2913. doi: 10.1001/jama.2008.896
12. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Gara J, Gniadkowski M, Hayden MK, Kumarasamy K, Livernois DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Vatopoulos A, Weber JT, Monnet DL (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13: 785–796. doi: 10.1016/S1473-3099(13)70190-7. Review
13. Glaser C, Albigé B, Buis G, Tamba Andrasievici A, Canton R, Carmeli Y, Friedrich AW, Giske CG, Głębucki Y, Gniadkowski M, Livernois DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Donker T, Monnet DL, Grundmann H; European Survey on Carbapenem-Producing Enterobacteriaceae (EuSCAPE) Working Group (2013) Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 18, pii: 20525. Erratum in: Euro Surveill 2013;18. pii: 20575. Euro Surveill 2014;19(47): pii: 20972
14. Dortet L, Poirel L, Errenra C, Nordmann P (2014) CarbAcineteto NP test for rapid detection of carbapenemase-producing Acinetobacter spp. J Clin Microbiol 52:2359–2364. doi: 10.1128/JCM.00594-14
15. Dortet L, Poirel L, Nordmann P (2012) Rapid detection of carbapenemase-producing Pseudomonas spp. J Clin Microbiol 50:3773–3776. doi: 10.1128/JCM.01597-12
16. Dortet L, Poirel L, Nordmann P (2014) Further proofs of concept for the Carba NP test. Antimicrob Agents Chemother 58:1269. doi: 10.1128/AAC.01825-13
17. Tijet N, Boyd D, Patel SN, Mulvey MR, Melano RG (2014) Reply to “Further proofs of concept for the Carba NP test”. Antimicrob Agents Chemother 58:1270. doi: 10.1128/AAC.02285-13
18. Dortet L, Bréchard L, Poirel L, Nordmann P (2014) Impact of the isolation medium for detection of carbapenemase-producing Enterobacteriaceae using an updated version of the Carba NP test. J Med Microbiol 63:772–776. doi: 10.1099/jmm.0.071340-0
19. Pires J, Novais A, Peixe L (2013) Blue-carba, an easy biochemical test for detection of diverse carbapenemase producers directly from bacterial cultures. J Clin Microbiol 51:4281–4283. doi:10.1128/JCM.01634-13

20. Bakour S, Garcia V, Loucif L, Brunel JM, Gharout-Sait A, Touati A, Rolain JM (2015) Rapid identification of carbapenemase-producing Enterobacteriaceae. Pseudomonas aeruginosa and Acinetobacter baumannii using a modified Carba NP test. New Microbes New Infect 7:89–93. doi:10.1016/j.nmni.2015.07.001

21. Pasteran F, Tijet N, Melano RG, Corso A (2015) Simplified protocol for Carba NP test for enhanced detection of carbapenemase producers directly from bacterial cultures. J Clin Microbiol 53:3908–3911. doi:10.1128/JCM.02032-15

22. Poirel L, Nordmann P (2015) Rapidec Carba NP test for rapid detection of carbapenemase producers. J Clin Microbiol 53:3003–3008. doi:10.1128/JCM.00977-15

23. Novais Â, Brilhante M, Pires J, Peixe L (2015) Evaluation of the recently launched Rapid CARB Blue kit for detection of carbapenemase-producing Gram-negative bacteria. J Clin Microbiol 53:3105–3107. doi:10.1128/JCM.01170-15

24. AbdelGhani S, Thomson GK, Snyder JW, Thomson KS (2015) Metallo-beta-lactamase VIM-2 in clinical isolates of Pseudomonas aeruginosa from Portugal. Microb Drug Resist 8:93–97

25. Woodford N, Tierno PM Jr, Young JK, Tysall L, Palepou M-FI, Ward E, Painter RE, Suber DF, Shungu D, Silver LL, Inglina K, Kornblum J, Livermore DM (2004) Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class beta-lactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 48:4793–4799

26. Chong PM, McCorrister SJ, Unger MS, Boyd DA, Mulvey MR, Westmacott GR (2015) MALDI-TOF MS detection of carbapenemase activity in clinical isolates of Enterobacteriaceae spp., Pseudomonas aeruginosa, and Acinetobacter baumannii compared against the Carba-NP assay. J Microbiol Methods 111:21–23. doi:10.1016/j.mimet.2015.01.024

27. Papagiannitsis CC, Študentová V, Izdebski R, Oikonomou O, Pfeifer Y, Petinaki E, Hrabák J (2015) Matrix-assisted laser desorption ionization-time of flight mass spectrometry meropenem hydrolysis assay with NH4HCO3, a reliable tool for direct detection of carbapenemase activity. J Clin Microbiol 53:1731–1735. doi:10.1128/JCM.00965-15

28. Morey KE, Vega R, Cassidy PM, Buser GL, Rayar JK, Myers JA, Weissman SJ, Beldavs ZG, Pfeiffer CD (2016) Evaluation of the Carba NP Test in Oregon, 2013. Antimicrob Agents Chemother 61:e03005-15. doi:10.1128/AAC.03005-15